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Abstract
Background: Because of the difficulties in acquiring large numbers of megakaryocytes, the 
impact of inflammatory responses on these cells and their ability to produce fully functional 
platelets under various pathological conditions has not been investigated in detail.
Objectives: The primary objective of this study is to develop and functionally charac-
terize a novel megakaryocyte nuclear factor κB (NF-κB) reporter cell line to determine 
the effects of various inflammatory molecules on megakaryocytes and their signalling 
pathways.
Methods: A Meg-01-NF-κB-GFP-Luc (Meg-01R) cell line was developed by inserting 
a reporter NF-κB-GFP-Luc cassette into normal Meg-01 cells to produce luciferase 
following activation of NF-κB to enable easy detection of pro-inflammatory and re-
parative signalling.
Results and conclusions: Meg-01 and Meg-01R cells have comparable characteristics, 
including the expression of both GPIbα and integrin β3. Meg-01R cells responded to 
various inflammatory molecules as measured by NF-κB-dependent bioluminescence. 
For example, inflammatory molecules such as tumor necrosis factor-α and Pam3CSK4 
increased NF-κB activity, whereas an antimicrobial peptide, LL37, reduced its activity. 
Meg-01R cells were also found to be sensitive to inhibitors (IMD0354 and C87) of in-
flammatory pathways. Notably, Meg-01R cells were able to respond to lipopolysaccha-
ride (LPS; non-ultrapure), although it was not able to react to ultrapure LPS because of 
the lack of sufficient TLR4 molecules on their surface. For the first time, we report the 
development and characterization of a novel megakaryocyte NF-κB reporter cell line 
(Meg-01R) as a robust tool to study the inflammatory responses/signalling of megakar-
yocytes upon stimulation with a broad range of inflammatory molecules that can affect 
NF-κB activity.
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1  | INTRODUC TION
Platelets (small circulating blood cells) are known for their ability to 
regulate hemostatic, innate immune, and inflammatory responses.1,2 
A large number of studies have focused on elucidating the roles 
of platelets in the regulation of innate immune/inflammatory re-
sponses and the molecular mechanisms responsible for these activi-
ties.1,3-5 Furthermore, platelets are recognized as having prominent 
roles in the adaptive immune system.1,2 However, only a relatively 
small number of studies have focussed on determining the impact on 
megakaryocytes (MKs), the precursors of platelets, on immune/in-
flammatory responses.6,7 This is an under researched area, although 
the reactivity and proteome of platelets produced during inflamma-
tion are modified to accustom the pathological conditions.8-10
MKs differentiate from hematopoietic stem cells (the progen-
itor cells from which innate immune cells such as neutrophils and 
monocytes are also derived), produce large quantities of proteins, 
and possess an extended invaginated membrane system for pack-
aging into numerous platelets.7 MKs in the bone marrow produce 
platelets by extending proplatelets into sinusoids, where the 
shear flow of blood leads to budding of platelets into the blood-
stream.7,11 Platelets are also produced in the mouse lungs, where 
MKs may interact with pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs); 
however, whether this function translates into humans remains 
unclear.12 The environment surrounding MKs may alter the func-
tions of platelets, for example, producing platelets that are more 
pro-aggregatory or aggressive toward pathogens, although the 
molecular mechanisms behind these actions are still poorly un-
derstood.8-10 Studies have shown that in mice, lipopolysaccharide 
(LPS) from Gram-negative bacteria causes an increase in circu-
lating platelet count.8 Mice lacking functional Toll-like receptor 
(TLR)-4 (the receptor for LPS) have a significant reduction in the 
number of circulating platelets.8 Furthermore, some studies sug-
gest that LPS treatment increases platelet production from MKs, 
as well as MK ploidy,13,14 although this may be due to the release 
of several factors from macrophages.15 Hence, determining the 
impact of inflammatory responses on MKs and subsequent plate-
let production will aid in better understanding of the significance 
of MKs and platelets in the regulation of thromboinflammation in 
various pathophysiological scenarios.
Meg-01 is a megakaryoblastic cell line frequently used as a sur-
rogate for elucidating signalling pathways and functions in MKs 
because of the difficulties associated with acquiring large num-
bers of primary MKs.16-19 TLR2 is closely related to TLR4 and it 
signals through the same MyD88-dependent pathway. A previous 
study has reported that the treatment of Meg-01 cells and murine 
MKs with a TLR2 agonist, Pam3CSK4, resulted in increased MK 
ploidy, activated nuclear factor-κB (NF-κB), and altered protein 
expression16; these results suggest that the MyD88-dependent 
pathway is likely to be active in MKs. Because of the lack of a 
reliable system to determine the role of MKs in the regulation of 
inflammatory responses, in this study we developed and charac-
terized a robust, Meg-01-NFκB-Luc-GFP (Meg-01R) reporter cell 
line for investigating the effect of inflammatory molecules on an 
MK-like cell line.
2  | MATERIAL S AND METHODS
The raw data that support the findings of this study are available 
upon reasonable request.
2.1 | Cell culture
Meg-01 cells were grown in RPMI-1640 media supplemented with 
10% (v/v) foetal calf serum (FCS) and 2 mM l-glutamine (Sigma-
Aldrich). Cells were kept at 37°C in a humidified 5% CO2 incuba-
tor. Every 2 to 3 days, the cells were removed by scraping, counted, 
and resuspended at a concentration of 2.5 × 105cells/mL in a vented 
suspension flask (Sarstedt). The media for Meg-01R cells was sup-
plemented with 1 μg/mL puromycin for selection (Apollo Scientific). 
All experiments were conducted in the absence of antibiotics and 
antimycotics.
THP-1 cells were grown in RPMI-1640 media supplemented with 
10% (v/v) FCS, 0.2% (v/v) penicillin/streptomycin mix, and 0.4% (v/v) 
amphotericin B (Sigma-Aldrich). These cells were kept in a humidi-
fied 5% CO2 incubator at 37°C.
HEK-293 cells were grown in high glucose DMEM containing 
10% (v/v) FCS and 2 mM L-glutamine in a humidified 5% CO2 incu-
bator at 37°C.
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Essentials
• An easily detectable readout in megakaryocyte cell lines 
will enhance inflammatory research in these cells.
• Here, we report the development and characteriza-
tion of a novel megakaryocyte NF-κB-reporter cell line 
(Meg-01R).
• Multiple inflammatory molecules modulate NF-κB activ-
ity in Meg-01R cells.
• Meg-01R cells respond to small molecule inhibitors such 
as IMD0354 and C87 that are known to inhibit NF-κB 
activity upon stimulation with TNFα.
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Doubling time was calculated using Meg-01 and Meg-01R cells 
cultured in parallel under normal growth conditions in normal growth 
media using the formula:
2.2 | Immunoblotting
Meg-01 and THP-1 lysates were immunoblotted following a pre-
viously established protocol.20-22 Further details are described in 
Appendix S1.
2.3 | RT-PCR
Total RNA was extracted from Meg-01 and Meg-01R cells and 
underwent RT-PCR to determine the presence of transcripts for 
MyD88. Further details are included in Appendix S1.
2.4 | XTT assay
Cell viability assays XTT assays were conducted according to manu-
facturer's instructions (Sigma-Aldrich). Further details are described 
in Appendix S1.
2.5 | Lentiviral transduction
Meg-01R cells were generated as described previously.23,24 Briefly, 
HEK-293 cells were transfected with pGreenFire-NFκB-Puro vec-
tor (System Biosciences) for viral production before transduction of 
Meg-01 cells. Viral production proceeded for 48 hours. Viral par-
ticles were isolated from HEK-293 cells by removing the cells with 
centrifugation for 10 minutes at 1000g (4°C). The supernatant was 
filtered through a 0.45-μm diameter filter and then centrifuged at 
100 000g for 1 hour at 4°C. The viral pellet was resuspended in 
phosphate-buffered saline (PBS) and left to precipitate overnight at 
4°C. To aid transduction of Meg-01 cells, 5 μg/mL of polybrene was 
added to the PBS-virus suspension and incubated with 3.75 × 106 
Meg-01 cells for 30 minutes at 4°C. Following transduction, nor-
mal cell culture medium (RPMI-1640 with 10% FCS and 2 mM 
L-glutamine) was added, and the cells were left for 96 hours before 
the addition of 1 μg/mL puromycin for the selection of transduced 
cells. Dead cells were removed via an extra centrifugation step (300g 
for 10 minutes) in PBS.
2.6 | Flow cytometry
Meg-01R cells were washed in PBS, centrifuged at 300g for 5 min-
utes, and resuspended in sterile-filtered 0.2% formyl saline (0.9% 
[w/v] NaCl and 0.2% [v/v] formaldehyde) for 10 minutes at room 
temperature. Following fixation, cells were blocked with 10% (v/v) 
FcR blocking reagent (Miltenyi Biotec) in PBS (for nonpermeabilized 
samples) or 0.02% (v/v) polybutylene terephthalate (for permeabi-
lized samples; PBS containing Triton X-100) for 30 minutes at room 
temperature.
For GPIbα (CD42b) and integrin β3 (CD61) staining, cells were in-
cubated with 1/50 dilution of anti-CD42b (SP219) rabbit antibody or 
1/50 dilution of anti-CD61 (CRC54) mouse antibody (Abcam) in PEB 
buffer (PBS with 2 mM ethylenediaminetetraacetic acid and 0.5% 
[w/v] bovine serum albumin) for 20 minutes at room temperature. 
Cells were then washed in PEB and incubated with anti-rabbit Alexa 
Fluor 647 or anti-mouse Alexa Fluor 647 (ThermoFisher Scientific) 
respectively for 20 minutes in the dark. Finally, cells were diluted 
1/10 in PEB and analyzed by flow cytometry (Accuri C6 Sampler 
Plus, BD Biosciences). The significant increase in background fluo-
rescence in Meg-01R cells was subtracted to enable accurate com-
parison of receptor levels.
For TLR4 staining, cells were incubated with 1/10 dilution of 
anti-TLR4 CD284-PE (HTA125) antibody or its isotype IgG2a-PE 
control (Miltenyi Biotec) in PEB in the dark at room tempera-
ture. Samples were then washed twice with PEB before analysis 
of the samples by flow cytometry (Accuri C6 Sampler Plus, BD 
Biosciences).
2.7 | Luciferase assay
The luciferase assay performed in this study was based on previous 
experiments.23 Briefly, 3.75 × 105 Meg-01R cells were seeded into 
a 24-well suspension plate in starvation media (RPMI-1640 with 2 
mM L-glutamine) and left at 37°C in a 5% CO2 incubator for 4 hours. 
Treatments were introduced to cells in RPMI-1640 containing 20% 
(v/v) FCS and 2 mM L-glutamine. For experiments involving inhibi-
tors (BML-111, IMD0354, C87, or 1,8-cineole), Meg-01R cells were 
incubated with the inhibitor during and after the starvation period. 
Following induction, cells were incubated for 24 hours. Meg-01R 
cells were removed and any remaining adherent cells were rinsed 
off with media and collected. Meg-01R cells were washed before 
resuspension in cell lysis buffer (Promega). Each sample was agitated 
for 2 hours and then centrifuged at 5000g for 5 minutes at room 
temperature. NF-κB-mediated luciferase activity was measured by 
the addition of luciferin (Promega) and the level of luminescence at 
all wavelengths was recorded using a SpectraMax iD3 multimode 
microplate reader (Molecular Devices).
2.8 | Confocal microscopy
For each condition, 1 × 106 Meg-01 cells were stained in suspension. 
Cells were fixed in 4% (w/v) paraformaldehyde for 10 minutes before 
blocking with FcR blocking reagent in PBS (nonpermeabilized) or 0.02% 
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anti-TLR4 antibody (Abcam) was used to detect TLR4 after incubation 
with cells for 1 hour at room temperature. A 1/300 dilution of Alexa 
Fluor 555-conjugated goat anti-mouse IgG antibody (ThermoFisher 
Scientific) was used to visualize binding of the anti-TLR4 antibody to 
its target. Finally, the nuclei of Meg-01 cells were stained with 1/2000 
4′,6-diamidino-2-phenylindole before resuspension in Mowiol 4-88 
(Sigma-Aldrich) and mounting on a microscope slide. Slides were then 
imaged using a Nikon A1R confocal microscope and images were pro-
cessed using Nikon NIS-Elements software and ImageJ.
2.9 | Statistical analysis
Logarithmic dose-response curves for puromycin toxicity were gen-
erated using a four-parameter curve with variable slope. For cell 
doubling time, an unpaired Student's t test was used to compare the 
mean values. For grouped data, analysis was performed using multi-
ple t tests with the type I error rate controlled for using the Holm-
Sidak method. For experiments containing multiple comparisons, 
data were analyzed using a one-way analysis of variance (ANOVA) 
with Bonferroni's post-hoc test. All statistical analysis was con-
ducted using GraphPad Prism 8 (GraphPad). Data are represented as 
mean ± standard deviation.
3  | RESULTS
3.1 | Meg-01 cells express various signalling 
proteins involved in TLR4 pathways
Platelets are reported to contain all the signalling proteins that are 
involved in MyD88-dependent and MyD88-independent signal-
ling pathways.25 Here, to determine whether Meg-01 cells are ca-
pable of inducing MyD88-dependent and -independent signalling 
upon ligation of inflammatory molecules such as LPS with TLR4, 
immunoblotting analysis was performed using Meg-01 cell lysates 
to confirm the presence of various signalling proteins. Meg-01 cell 
lysate was tested concurrently with an equivalent mass of THP-1 
cell (a monocyte cell line capable of responding to LPS26) lysate as 
a positive control. As expected, THP-1 cells express notable levels 
of TLR4, MyD88, IRAK2, TRAF6, IKKγ, IKKα, IKKβ, IκBα, p65, TRIF, 
TRAF3, TBK1, IRF3, and control proteins 14-3-3ζ and α-tubulin 
(Figure 1A). Although all of these proteins were detectable in Meg-
01 cells, surprisingly we could not detect MyD88 via this method. 
However, MyD88 mRNA was detectable via RT-PCR using specific 
primers for MyD88 (Figure 1B). This discrepancy may be due to the 
expression level of this protein being below the detection threshold 
of the immunoblotting technique or antibody sensitivity. Notably, a 
previous study16 has shown that Meg-01 cells are able to respond 
Pam3CSK4; therefore, MyD88-dependent signalling is likely to be 
active in these cells.
F I G U R E  1   Presence of proteins involved in Toll-like receptor 
4 signalling pathways in Meg-01 cells. A, Whole cell Meg-01 
and THP-1 lysates were investigated via immunoblotting for the 
expression of TLR4, MyD88, IRAK2, TRAF6, IKKγ, IKKα, IKKβ, 
IκBα, p65, TRIF, TRAF3, TBK1, and IRF3. 14-3-3ζ and α-tubulin 
were detected as loading controls. Proteins were detected either 
via fluorescence or enhanced chemiluminescence based on the 
secondary antibodies used. B, RT-PCR was used to investigate the 
presence of mRNA for MyD88 and GAPDH in both Meg-01 and 
























































F I G U R E  2   Characterization of Meg-01 and Meg-01R cells. A, Meg-01 cells were treated with puromycin and their viability was tested 
by an XTT assay to determine the susceptibility of naïve cells. Data represent mean ± SD after 24 or 48 hours’ incubation of 5 × 104 cells 
with puromycin (n = 3). B, The growth rate of Meg-01 and Meg-01R cells was compared to determine if the transduction process hindered 
growth. Data was analyzed using a Student's t test (n = 3). C, An XTT assay using different cell concentrations was performed to determine 
if the transduction process altered cell viability. Data were analyzed using multiple t tests corrected using the Holm-Sidak method (n = 3). D, 
The morphology of Meg-01 at 10× (i) and 40× (ii) and Meg-01R cells at 10× (iii) and 40× (iv) were compared using light microscopy. Scale bar 
represents 400 μm at 10× and 100 μm at 40×. Images shown are representative of five regions of interest taken from three separate flasks. 
Expression of GPIb (E) and integrin β3 (F), intracellularly and on the surface of Meg-01 and Meg-01R cells, were compared to determine if the 
transduction process had modified the expression of specific receptors in MKs. Data were analyzed using multiple t tests comparing controls to 
antibody and Meg-01 to Meg-01R corrected via the Holm-Sidak method (n = 4 and n = 3, respectively). Furthermore, whole cell lysates were 
investigated via immunoblot analysis (representative blots shown in Gi) for the presence of GPIb and integrin β3 (Gii). Data were analyzed using 
multiple t tests to compare Meg-01 to Meg-01R and corrected via the Holm-Sidak method (n = 3). For clarity, nonsignificant differences are not 
shown. The P values (*P < .05) are as calculated by GraphPad Prism
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3.2 | Development of a Meg-01R (NF-κB) reporter 
cell line
Viral particles containing the NF-κB reporter sequence were gener-
ated from HEK-293 cells to develop an NF-κB reporter Meg-01 cell 
line (Meg-01R), to aid in determination of the role of MK-like cells 
during inflammation. A commercially available luciferase gene was 
used to produce a nonendogenous protein whose activity is easily 
detectable.27 Successful transduction was confirmed by stimulating 
Meg-01R cells with tumor necrosis factor-α (TNF-α) and subsequently 
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The optimal concentration of puromycin required to eradicate 
~80% of nontransfected Meg-01 cells was determined using an XTT 
assay (Figure 2A). The results demonstrate that puromycin was ca-
pable of inducing cell death both over 24- and 48-hour time scales 
with a half maximal effective concentration of 760 and 560 ng/mL, 
respectively. Based on these results, a concentration of 1 μg/mL pu-
romycin was used to select transduced cells, which contain a puro-
mycin-resistance gene, in subsequent experiments.
To elucidate differences or similarities between the trans-
duced Meg-01R and standard Meg-01 cells, the doubling 
time of these cells was compared. The growth rate of Meg-01 
(50.7 ± 4.35 hours) and Meg-01R (53.2 ± 6.28 hours) cells cultured 
parallelly was not significantly different (Figure 2B). Moreover, 
their viability was determined using an XTT assay and it did not 
show any significant differences after 6 hours except a slight re-
duction in the viability of Meg-01R cells observed when they were 
seeded at 2 × 105 cells/mL (Figure 2C). This slight reduction may 
be explained by the presence of 1 μg/mL puromycin throughout 
the experiment to prevent nontransfected cells from interfering 
with the results. To investigate whether the transduction altered 
the cellular morphology, light microscopy was used to analyze 
Meg-01 and Meg-01R cells. Meg-01 cells at both 10× (Figure 2Di) 
and 40× (Figure 2Dii) exhibited a spherical morphology when 
cultivated in suspension; the same morphology was observed in 
Meg-01R cells (Figure 2Diii-2Div). Furthermore, the expression of 
specific cell receptors was investigated by flow cytometry. GPIbα 
was detectable in permeabilized and intact cells of both Meg-01 
and Meg-01R at similar levels (Figure 2E). Moreover, integrin β3 
was detectable in both permeabilized and intact Meg-01 and Meg-
01R cells at similar levels (Figure 2F).19 To corroborate these data, 
GPIbα and integrin β3 expression levels were analyzed using im-
munoblots, and they were found to not be significantly different 
in Meg-01 and Meg-01R cell lysates (Figure 2G). Together, these 
data suggest that the transduction in Meg-01R cells did not affect 
the proliferation, growth, and major characteristics of these cells 
compared with Meg-01.
F I G U R E  3   Impact of inflammatory molecules on NF-κB activity in Meg-01R cells. Meg-01R cells were incubated with TNF-α (A), or 
a TLR1/2 agonist Pam3CSK4 (B) for 24 hours and the level of NF-κB activity was recorded. Furthermore, NF-κB activity was recorded 
in Meg-01R cells challenged with various concentrations of a TLR3 agonist, Poly(I:C) (C), or ultrapure (D) or non-ultrapure (E) versions of 
the TLR4 agonist LPSEC for 24 hours. The level of NF-κB activity was measured by quantifying the level of luminescence. Data represent 
mean ± standard deviation (n = 3) and statistical significance was calculated using a one-way ANOVA with Bonferroni post hoc test. 
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3.3 | Inflammatory molecules stimulate NF-κB 
activity in Meg-01R cells
To determine whether Meg-01R cells respond to various inflam-
matory molecules, luciferase assays to detect NF-κB-dependent 
bioluminescence were performed as a measure for NF-κB activ-
ity. Meg-01R cells were incubated with increasing concentrations 
of TNF-α (Figure 3A; a ligand for tumor necrosis factor receptor I 
and II [TNFRI/II], both of which are expressed on Meg-01 cells18), 
Pam3CSK4 (Figure 3B; a ligand for TLR1/216), Poly(I:C) (Figure 3C; 
a ligand for TLR328), ultrapure LPS from Escherichia coli (uLPSEC [a 
ligand for TLR420; Figure 3D]) and non-ultrapure LPSEC (Figure 3E) 
24 hours before lysis, and addition of luciferin to measure the 
NF-κB activity. The results suggest that TNF-α induced significant 
NF-κB-dependent bioluminescence in a concentration-dependent 
manner (from 1.25 to 10 ng/mL). Similarly, Pam3CSK4 increased 
NF-κB activity at 5 and 10 μg/mL. In contrast, Poly(I:C) did not 
significantly increase NF-κB activity at the concentrations tested. 
Interestingly, although uLPSEC was incapable of inducing NF-κB 
activity from Meg-01R cells, the non-ultrapure preparation tested 
was able to stimulate significant NF-κB activity. These results 
demonstrate that Meg-01R cells produce functional luciferase as 
a marker for NF-κB activity and successfully respond to various 
inflammatory molecules.
3.4 | FPR2/ALX ligands do not modulate NF-κB 
activity in Meg-01R cells
FPR2/ALX, a seven-transmembrane receptor that couples to Gi 
proteins, is involved in the regulation of the innate immune sys-
tem and has been found to be expressed on platelets.29-32 Because 
the ligands of FPR2/ALX perform both pro-inflammatory and re-
parative activities, their impact on modulating NF-κB activity 
was analyzed in Meg-01R cells. LL37 (an FPR2/ALX agonist that 
is known to activate platelets31), Ac2-26 (an annexin-1 mimetic 
F I G U R E  4   Effect of FPR2/ALX ligands on NF-κB activity of Meg-01R cells. Various ligands for FPR2/ALX were tested at different 
concentrations to determine their impact on NF-κB activity in Meg-01R cells over a 24-hour period. The FPR2/ALX agonist LL37 (A), the 
annexin A1-mimetic peptide, Ac2-26 (B), and amyloid-β (C) were tested in the absence of an inflammatory stimulus. A synthetic FPR2/
ALX ligand, BML-111 (D) was tested (pretreated) in both the presence and absence of 2.5 ng/mL TNF-α. Data represent mean ± standard 
deviation (n = 3) and statistical significance was calculated using a one-way ANOVA with Bonferroni post hoc test. The P values (***P < .001 
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peptide that acts as a pro-resolution mediator to control inflam-
mation33), and amyloid-β1-42 (reported to act via TLR2/4, FPR2/
ALX, and RAGE23,34) were tested in unstimulated Meg-01R cells. 
LL37 was able to significantly inhibit NF-κB activity when used at 
a concentration of 10 μM (Figure 4A), whereas Ac2-26 (Figure 4B) 
and amyloid-β1-42 (Figure 4C) were unable to modulate NF-κB ac-
tivity at any of the concentrations tested. Furthermore, BML-111 
(a synthetic lipoxin A4 analogue and ligand for FPR2/ALX that is 
known as a pro-resolution mediator35) was tested at a range of 
concentrations in both the presence and absence of 2.5 ng/mL 
TNF-α. In these experiments, TNF-α was able to significantly in-
duce the NF-κB activity over 24 hours. However, pretreatment 
of Meg-01R cells with BML-111 (Figure 4D) was unable to signifi-
cantly modulate the NF-κB activity in either TNF-α-stimulated or 
unstimulated Meg-01R cells. Further experiments would be nec-
essary to determine the mechanisms that regulate the effects of 
LL37 in Meg-01R cells in line with the expression and significance 
of FPR2/ALX in Meg-01 cells.
3.5 | Small molecule inhibitors reduce TNF-α-
induced NF-κB activity in Meg-01R cells
IMD0354, C87, and 1,8-cineole were reported as small molecule 
inhibitors that are able to affect TNF-α-induced NF-κB activity 
in other cell types. IMD0354 acts as an inhibitor of IKKβ to pre-
vent the phosphorylation and subsequent degradation of IκB.23,36 
C87 acts as an antagonist to TNF-α by directly binding to TNF-α 
and thus has been proposed to disrupt the TNF-α-TNFRI/II com-
plex.37,38 The 1,8-cineole is a plant-derived compound that has 
been shown to inhibit nuclear translocation of p65 and degrada-
tion of IκBα.24,39 Here, these compounds were tested to determine 
their impact on TNF-α-mediated NF-κB activity in Meg-01R cells. 
In the absence of TNF-α, IMD0354 (Figure 5A), C87 (Figure 5B), 
and 1,8-cineole (Figure 5C) do not alter the NF-κB activity in Meg-
01R cells. However, when cells were stimulated with 2.5 ng/mL 
TNF-α, IMD0354 significantly inhibited NF-κB in a dose-depend-
ent manner. C87 was also capable of inhibiting NF-κB activity in 
Meg-01R cells at 20 μM. Interestingly, C87 mildly potentiated 
TNF-α-induced NF-κB activity at 1.25 μM; however, this increase 
was not observed at higher concentrations. 1,8-cineole was, how-
ever, unable to inhibit TNF-α-induced NF-κB activity in Meg-01R 
under the current settings used. These results demonstrate that in 
addition to the impact of inflammatory molecules, the inhibitory 
potential of various small molecule inhibitors on NF-κB activity 
can also be determined using Meg-01R cells.
F I G U R E  5   Impact of TNF-α pathway inhibitors on NF-κB 
activity in Meg-01R cells. Different concentrations of an IKKβ 
inhibitor, IMD0354 (A), a TNF-α antagonist C87 (B), and 1,8-cineole 
(C) were tested in both the presence and absence of 2.5 ng/mL 
TNF-α over a 24-hour period. Data represent mean ± standard 
deviation (n = 3) and statistical significance (*P < .05, **P < .01, 
and ****P < .0001) was calculated using a one-way ANOVA 
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3.6 | TLR4 is predominantly present inside Meg-01/
Meg-01R cells
To further scrutinize the lack of Meg-01R response to the ul-
trapure preparation of LPS, the level of TLR4 expression on the 
surface and inside of Meg-01 and Meg-01R cells was examined. 
The results obtained using confocal microscopy demonstrate that 
TLR4 is largely detectable inside Meg-01 cells as only the permea-
bilized cells show strong binding to anti-TLR4 antibodies (Figure 6A 
and 6B). The z-stack image in Figure 6C further demonstrates that 
TLR4 is expressed ubiquitously within the cytoplasm.
Additionally, the absence of TLR4 on the surface of Meg-01R cells 
was corroborated using a flow cytometry-based assay. Here, the bind-
ing of an anti-TLR4 antibody to the surface of Meg-01R cells was not 
F I G U R E  6   Expression of TLR4 in Meg-01 and Meg-01R cells. A, 20× magnification images of fluorescently labelled Meg-01 cells acquired via 
confocal microscopy. Images represent non-permeabilized negative control, permeabilized negative control, permeabilized cells with the anti-TLR4 
antibody present, and non-permeabilized cells with an anti-TLR4 antibody present (clockwise from the top left). Scale bar shows 100 μm. B, Same as 
A, but images were acquired with 100× magnification. Scale bar denotes 10 μm. C, Three-dimensional reconstruction of Meg-01 cells taken with a 
100× objective showing the distribution of TLR4 in the cytoplasm. In all images, nuclei have been stained with 4′,6-diamidino-2-phenylindole (cyan) 
and the anti-TLR4 antibody is shown in magenta. D, Flow cytometry-based assays were used to quantify the level of TLR4 by quantifying antibody 
binding to both permeabilized and non-permeabilized Meg-01R cells. Median fluorescence intensity of TLR4 expression in non-permeabilized and 
permeabilized Meg-01R cells (n = 3) was calculated. Data represent mean ± standard deviation and were analyzed using multiple t tests with the 
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significantly different from the isotype controls (Figure 6D). Conversely, 
the binding of the anti-TLR4 antibody was significantly greater in per-
meabilized cells compared with their isotype control. These results 
demonstrate the reasons for the lack of response of Meg-01R cells to 
ultrapure LPS (detailed previously). Further experiments are required 
to determine whether activating Meg-01R cells with specific molecules 
(for example, valproic acid) might elevate the levels of TLR4 on the sur-
face, which would then enable ligation with LPS molecules to exert in-
flammatory effects (in this case, NF-κB activity).
3.7 | CD14 and LL37 do not enable LPS to stimulate 
NF-κB activity in Meg-01R cells
To determine if TLR4-induced NF-κB activity could be promoted 
by cluster of differentiation 14 (CD14; a TLR4 co-receptor5,40,41) or 
LL37 (a molecule capable of binding LPS42-44), the assays were per-
formed in the presence and absence of these molecules along with 
LPS chemotypes. LL37 has been shown to be capable of transmitting 
LPS across the cell membrane of human epithelial cells.43
Meg-01R cells were co-incubated with uLPSEC or ultrapure 
Salmonella minnesota LPS (uLPSSM) for 24 hours with/without CD14 
or LL37. A physiologically relevant concentration of 2μg/mL was 
chosen for CD14.45 The results show that CD14 did not significantly 
alter NF-κB activity in Meg-01R cells on its own, and it was not ca-
pable of promoting uLPSEC or uLPSSM to stimulate NF-κB activity 
(Figure 7A). Furthermore, LPS chemotypes did not induce any activ-
ity on their own. When LL37 and uLPSEC or uLPSSM were added si-
multaneously (Figure 7B) or following 15 minutes preincubation with 
LL37 (Figure 7C), there was no change in NF-κB activity compared 
with LL37 alone (Figure 7C). These results demonstrate that CD14 
and LL37 do not modulate LPS-induced NF-κB activity.
4  | DISCUSSION
The role of MKs during inflammation is not fully understood. 
Thrombopoietin is known to stimulate the growth and develop-
ment of MKs and it is removed from the plasma by platelets, which 
means that, during thrombocytopenia (which can be induced by 
inflammatory diseases such as sepsis5), high levels of thrombopoi-
etin are detected in the plasma.7,46 Very few studies have been 
F I G U R E  7   Effect of LPS-binding molecules CD14 and LL37 to 
induce LPS-mediated NF-κB activity in Meg-01R cells. NF-κB activity 
was measured in lysates from Meg-01R cells that were stimulated 
with uLPSEC or uLPSSM in the presence of 2 μg/mL CD14 (A; n = 3), or 
10 μM LL37 following no co-incubation before addition (B; n = 6) or 
15 minutes co-incubation (C; n = 5). Data represent mean ± standard 
deviation and statistical significance was calculated using a one-way 
ANOVA with Bonferroni post hoc test. The P values (**P < .01 and 
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conducted to examine the effect of PAMPs using MK cell lines but 
they demonstrate that NF-κB can be activated.16,28 Mice lacking 
TLR4 have significantly lower platelet counts than their wild-type 
counterparts but intravenous injection of a sublethal dose of LPS 
(0.2 mg/kg) leads to a significant increase in platelet count regard-
less of whether TLR4 was present.8 Moreover, TLR2 and TLR4 
have been shown to induce the production of interleukin-6 (IL-6), 
via NF-κB, in CD34+ cells, which leads to increased MK matura-
tion and platelet production.13 Furthermore, circulating platelets 
have been shown to have higher expression of TLR2 and TLR4 in 
particular disease states, which suggests that MKs can respond 
to inflammatory states to tailor the platelet phenotype to the al-
tered pathological situation.8,10,47 Moreover, as platelets are anu-
cleate cells and TLRs lead to activation of transcription factors, 
it has been suggested that platelet TLRs are relics from MKs or 
hemopoietic stem cells.6
TLR4 is unique among the TLR family of receptors in that it 
can signal via two distinct pathways.5 These pathways are known 
as the MyD88-dependent and the MyD88-independent path-
ways.48-50 TLR1, 2, 4, 5, 6, 7, 8, 9, and 10 can all activate the 
MyD88-dependent pathway, whereas TLR3 and TLR4 activate 
the MyD88-independent pathway.5,48,51 Here, we demonstrate 
that a plethora of proteins required for both MyD88-dependent 
signalling (TLR4, IRAK2, TRAF6, IKKγ, IKKα, IKKβ, IκBα, and p65) 
and MyD88-independent signalling (TLR4, TRIF, TRAF3, TBK1/
NAK, and IRF3) are present in Meg-01 cells. Interestingly, MyD88 
was detectable in the THP-1 cells used as a positive control but 
was not detectable in Meg-01 via immunoblotting. This may be 
due to the low expression level of MyD88 in Meg-01 cells and/
or limitations of the antibodies used, as its presence was reported 
in platelets previously.25 However, mRNA of MyD88 was prom-
inently detected in both Meg-01 and Meg-01R cells, which sug-
gests that this protein is indeed present in these cells at similar 
levels. One complication with identifying proteins in Meg-01 cells 
and MKs, however, is their ability to produce platelet-like particles 
or platelets, respectively, because it can be difficult to ascertain 
whether the proteins are present for signalling in the progenitor 
cell or merely produced for packaging into the progeny.
IκB prevents binding of p65 (a member of the NF-κB family of 
transcription factors) to its specific DNA promoter sequence but is 
degraded following phosphorylation by IKKβ and ubiquitinated be-
fore its degradation.5,52,53 p65 is a transcriptional activator that en-
ables transcription of inflammatory cytokines in response to PAMPs 
and DAMPs, such as ligands of TLRs and TNF-α.5,53,54 The MyD88-
dependent pathway directly leads to NF-κB activation brought about 
by IκBα degradation; however, cross-talk between the two pathways 
mean that the MyD88-independent pathway can also induce NF-κB 
activation.5,28
Meg-01 cells and MKs are reported to express TLR1, 2, 3, 4, and 
6 and Meg-01 cells are frequently used as a surrogate for elucidating 
signalling pathways in MKs.16-19,28,55-57 Because these receptors all 
can induce NF-κB activation, we endeavored to develop a reporter 
cell line to determine the role of MKs in regulating inflammation. 
Therefore, we transfected HEK-293 cells with a previously published 
and commercially available reporter plasmid with a puromycin-resis-
tant gene (pGreenFire-NFκB-Puro) 23 to produce lentiviral particles 
that can stably transfect other cell types with this reporter con-
struct. Successfully transduced cells were selected with puromycin, 
a compound cytotoxic to mammalian cells. A concentration capable 
of killing ~ 80% of nontransduced Meg-01 cells was used to ensure 
that a pure population of Meg-01-GFP-Luc-NFκB-Puro (Meg-01R) 
cells developed.
Initially, the Meg-01R cell line was compared with Meg-01 cells 
to determine whether the transduction process adversely affected 
the cells or changed their phenotype. Growth rate and morphology 
remained constant throughout the two cell types and only a minor 
defect in viability was detected, which may be due to the presence 
of puromycin. Furthermore, Meg-01R cells express specific func-
tionally important proteins in the same compartments as Meg-01 
cells. The Meg-01R cells were then characterized by stimulating 
them with a range of PAMPs and DAMPs. First, a DAMP, TNF-α was 
tested for its effects as Meg-01 cells have been reported to express 
both TNFRI and TNFRII, two receptors that stimulate NF-κB activa-
tion.18,54 Indeed, TNF-α was able to significantly activate NF-κB to 
transcribe luciferase in a concentration-dependent manner as deter-
mined by the level of luciferase activity.
Pam3CSK4 is a synthetic ligand for the TLR1/2 heteroreceptor 
and it has previously been shown to induce phosphorylation of NF-
κB’s p65 subunit and degradation of IκB over the period of 1 hour.16 
Phosphorylation of p65 was also shown to occur in murine MKs fol-
lowing 30 minutes of treatment with Pam3CSK4.16 In accordance 
with this previous study, Pam3CSK4 was able to induce luciferase 
production downstream of NF-κB albeit not as strongly as the low-
est concentration of TNF-α tested.
Poly(I:C) is a synthetic ligand for TLR3 and, although TLR3 cou-
ples to the MyD88-independent pathway, signalling downstream 
of TLR3 can lead to NF-κB activation.28 Poly(I:C) and Poly(A:U) (an-
other synthetic TLR3 ligand) have been shown to induce IκB degra-
dation and phosphorylation of p65 in human CD34+ cells derived 
from umbilical blood.28 In this study, Poly(I:C) was incapable of stim-
ulating the NF-κB activity at any of the concentrations tested. This 
discrepancy may be due to changes in the expression levels of spe-
cific receptors and characteristics observed during MK maturation.
The preparation of LPSEC can alter the characteristics of the re-
sponses induced by this ligand therefore an ultrapure and a non-ul-
trapure version were both tested. This has been hypothesized to 
be due to the presence of bacterial contaminants in non-ultrapure 
preparations that can activate other pro-inflammatory receptors 
such as TLR2.20,51 The ultrapure version of LPSEC was unable to ac-
tivate NF-κB; however, the non-ultrapure preparation was capable 
of inducing activity at a range of concentrations. This finding lends 
more weight to the hypothesis that many of the effects observed 
when using non-ultrapure LPSEC may be induced by contaminants in 
the preparations.
Moreover, FPR2/ALX ligands were tested on Meg-01R cells to 
determine if they could affect NF-κB activity in this cell type. The 
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agonist, LL37,31 was able to significantly inhibit NF-κB activity on its 
own over a period of 24 hours in contrast to the annexin A1-mimetic, 
Ac2-26.33 Amyloid-β1-42 is a neuropeptide involved in the progres-
sion of Alzheimer's disease. Indeed, it has been related to inflam-
mation in the brain and is capable of inducing NF-κB activity in a 
glioblastoma cell line.23,34 However, amyloid-β1-42 was incapable of 
activating NF-κB at any of the tested concentrations in this study. 
This may be due to the concentrations tested being subthreshold. 
Interestingly, the synthetic lipoxin A4-analogue, BML-111 was in-
capable of modulating NF-κB activity in the absence or presence 
of TNF-α.35 However, this may be due to signalling via a different 
downstream pathway.
A potential application of this novel reporter cell line is for the 
identification of compounds that affect inflammatory responses 
in MKs during disease states in an NF-κB-dependent manner.15 To 
evaluate this, Meg-01R cells were treated with an IKKβ inhibitor, 
IMD0354,36 a TNF-α antagonist, C87,37 or 1,8-cineole for 24 hours 
in the presence or absence of TNF-α. Neither IMD0354 nor C87 
had a significant effect on unstimulated Meg-01R cells; however, 
they could both significantly inhibit the increase in NF-κB activity 
induced by TNF-α. Interestingly, the lowest concentration of C87 
tested (1.25 μM) potentiated the NF-κB activity induced by TNF-α 
although the mechanism behind this is currently unknown. 1,8-cin-
eole had no effect in either stimulated or unstimulated cells.
Meg-01 cells have previously been described to express TLR4 
when the cells were fixed with methanol, a fixative known to be ca-
pable of permeabilizing cells.56 To confirm the distribution of TLR4 
in Meg-01 cells, they were fixed with 4% PFA (for immunocyto-
chemistry) or 0.2% formyl saline (for flow cytometry) and then cells 
were left intact or permeabilized with PBS containing Triton-X100. 
Moreover, two different anti-TLR4 antibodies were used to con-
firm its presence depending on the detection method. With both 
methods, TLR4 was not detectable on the surface of Meg-01 cells; 
however, it was detectable intracellularly. Previous studies have sug-
gested that MKs express TLR4 on their surface but this increases 
during MK maturation.57
Although TLR3 is predominantly detectable intracellularly, 
poly(I:C) is capable of being internalized leading to its activation.28 
In contrast, LPS is not capable of crossing the cell membrane on 
its own.43 LPS is internalized after binding to CD14-TLR4 to en-
able it to enter endosomes and induce MyD88-independent sig-
nalling.40,41 Furthermore, LL37 is known to be capable of binding 
LPS and other negatively charged molecules, usually in an anti-in-
flammatory capacity.42-44,58,59 Shaykhiev et al.43 demonstrated, 
through the use of primary human bronchial epithelial cells and 
human pulmonary mucoepidermoid carcinoma NCI-H292 cell line, 
that 20 μg/mL LL37 can induce the uptake of LPS in epithelial cells 
over the course of 24 hours.43 Importantly, this internalization was 
shown to be independent of TLR4 and dependent of caveolae and 
functional epidermal growth factor receptor.43 Three treatments 
– 2 μg/mL CD14, simultaneous addition of 10 μM LL37 and LPS, 
addition of 10 μM LL37 and LPS after 15 minutes of co-incubation 
– were tested to determine if these molecules could deliver LPS 
to its target receptor. Two μg/mL CD14 had no effect on NF-κB 
activity in Meg-01R cells and was unable to promote LPS to in-
duce luciferase synthesis. Furthermore, in both conditions, LL37 
significantly inhibited NF-κB activity; however, this was not mod-
ulated by the simultaneous addition of LPS, nor the co-incubation 
of LL37 and LPS. This may suggest that TLR4 in Meg-01R cells 
is not found in the endosome and therefore it may not stimulate 
MyD88-independent signalling nor interact with internalized 
LL37/LPS complexes.
In conclusion, here we developed a MK reporter cell line and 
demonstrated that MKs are responsive to a range of PAMPs and 
DAMPs, and their pathway inhibitors. Hence, this reporter cell line 
can be applied to screen a broad range of inflammatory molecules 
that act via NF-κB to determine their functions in MKs.
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